Moderna, Inc. (MRNA) EBITDA Margin: -131.33%
Is Moderna, Inc.’s EBITDA margin high or low?
Moderna, Inc.'s EBITDA margin of -131.33% is 222% below its 5-year average of -40.82%, near the low end of its 5-year range (-131.33%–76.27%).
The EBITDA margin for Moderna, Inc. (MRNA) is -131.33% as of Tuesday, June 9, 2026. It is below its 12-month average by 10.63% (-118.72%).
MRNA EBITDA Margin Chart
MRNA Average EBITDA Margin Chart
MRNA Current vs Average EBITDA Margin Chart
MRNA EBITDA Margin Metrics
EBITDA MARGIN
-131.33%
EBITDA MARGIN AVG TTM
-118.72%
EBITDA MARGIN AVG 3Y
-58.41%
EBITDA MARGIN AVG 5Y
-40.82%
EBITDA MARGIN AVG 10Y
-164.92%
EBITDA MARGIN AVG 15Y
-164.92%
EBITDA MARGIN AVG 20Y
-164.92%
CURRENT VS TTM AVG
-10.63%
CURRENT VS 3Y AVG
-124.86%
CURRENT VS 5Y AVG
-221.76%
CURRENT VS 10Y AVG
+20.37%
CURRENT VS 15Y AVG
+20.37%
CURRENT VS 20Y AVG
+20.37%
MRNA Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | — | -131.33% | -118.72% | -58.41% | -40.82% |
| Hologic, Inc. (HOLX) | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| BioNTech SE (BNTX) | $21.87B | -9.29% | -11.31% | 22.27% | 24.39% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 30.67% | 31.14% | 31.31% | 30.59% |
| Waters Corporation (WAT) | $24.19B | 31.97% | 33.50% | 33.77% | 33.93% |
| Align Technology, Inc. (ALGN) | $12.76B | 18.98% | 19.70% | 20.24% | 21.31% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.68% | 27.64% | 24.37% | 25.68% |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | 22.69% | 18.52% | 21.71% | 22.71% |
| Biogen Inc. (BIIB) | $29.39B | 31.60% | 31.28% | 30.38% | 32.54% |
| Bio-Rad Laboratories, Inc. (BIO) | $8.03B | 18.42% | -32.52% | -62.43% | 23.50% |
Margin Comparison
Gross Margin
55.4%
EBITDA Margin
-131.3%
Operating Margin
-158.1%
Net Margin
-145.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Moderna, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Moderna, Inc. (MRNA)?
- The EBITDA margin for MRNA stock is -131.33%.
- Is Moderna, Inc.'s EBITDA margin high or low?
- Moderna, Inc.'s EBITDA margin of -131.33% is 222% below its 5-year average of -40.82%, near the low end of its 5-year range (-131.33%–76.27%).
- What is the TTM average EBITDA margin for Moderna, Inc. (MRNA)?
- The TTM average EBITDA margin for MRNA stock is -118.72%.
- What is the 3Y average EBITDA margin for Moderna, Inc. (MRNA)?
- The 3Y average EBITDA margin for MRNA stock is -58.41%.
- What is the 5Y average EBITDA margin for Moderna, Inc. (MRNA)?
- The 5Y average EBITDA margin for MRNA stock is -40.82%.
- What is the 10Y average EBITDA margin for Moderna, Inc. (MRNA)?
- The 10Y average EBITDA margin for MRNA stock is -164.92%.
- What is the 15Y average EBITDA margin for Moderna, Inc. (MRNA)?
- The 15Y average EBITDA margin for MRNA stock is -164.92%.
- What is the 20Y average EBITDA margin for Moderna, Inc. (MRNA)?
- The 20Y average EBITDA margin for MRNA stock is -164.92%.
Moderna, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -131.33% |
| 2024-12-31 | -106.10% |
| 2023-12-31 | -47.94% |
| 2022-12-31 | 51.75% |
| 2021-12-31 | 76.27% |
| 2020-12-31 | -87.55% |
| 2019-12-31 | -792.38% |
| 2018-12-31 | -305.07% |
| 2017-12-31 | -114.33% |
| 2016-12-31 | -192.50% |
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel